TrovaGene Inc (NASDAQ:TROV) Short Interest Update
Posted by Jeshia Costen on Jun 26th, 2019 // Comments off
?TrovaGene Inc (NASDAQ:TROV) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 621,000 shares, a decline of 12.0% from the April 15th total of 705,900 shares. Currently, 12.0% of the company’s stock are short sold. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 0.5 days.
An institutional investor recently raised its position in TrovaGene stock. Vanguard Group Inc. grew its stake in shares of TrovaGene Inc (NASDAQ:TROV) by 508.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 239,029 shares of the medical research company’s stock after acquiring an additional 199,767 shares during the period. Vanguard Group Inc. owned about 1.04% of TrovaGene worth $195,000 at the end of the most recent quarter. 6.04% of the stock is owned by hedge funds and other institutional investors.
Get TrovaGene alerts:
Shares of NASDAQ:TROV opened at $2.48 on Wednesday. The company has a 50-day simple moving average of $2.93. TrovaGene has a one year low of $2.43 and a one year high of $9.65. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $12.45 million, a PE ratio of -0.30 and a beta of 0.90.
TrovaGene (NASDAQ:TROV) last announced its earnings results on Tuesday, May 7th. The medical research company reported ($1.02) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.05. TrovaGene had a negative net margin of 3,540.91% and a negative return on equity of 121.65%. The business had revenue of $0.16 million during the quarter. On average, equities research analysts forecast that TrovaGene will post -4.02 earnings per share for the current fiscal year.
A number of equities analysts recently commented on TROV shares. ValuEngineupgraded shares of TrovaGene from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Noble Financial set a $20.00 target price on shares of TrovaGene and gave the stock an “outperform” rating in a research note on Friday, March 8th. Maxim Group reiterated a “buy” rating and set a $8.00 target price on shares of TrovaGene in a research note on Thursday, March 7th. Finally, Zacks Investment Researchupgraded shares of TrovaGene from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research note on Tuesday, March 12th.
TrovaGene Company Profile
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.
AI
